Literature DB >> 26057180

Age- and Sex-Dependent Distribution of OGTT-Related Variables in a Population of Cystic Fibrosis Patients.

Alberto Battezzati1, Giorgio Bedogni1, Laura Zazzeron1, Andrea Mari1, Pier Maria Battezzati1, Gianfranco Alicandro1, Simona Bertoli1, Carla Colombo1.   

Abstract

CONTEXT: Cystic fibrosis (CF) causes an exceptionally high prevalence of diabetes that increases with age, especially in females. The glucose tolerance defect is progressive, but a cystic fibrosis transmembrane conductance regulator-dependent insulin secretory defect cannot be excluded. The age and sex dependence of the secretory defect is unclear.
OBJECTIVE: The objective of the study was to analyze the age and sex dependency of insulin secretory and sensitivity parameters in CF.
DESIGN: This was a cross-sectional analysis in an observational ongoing cohort (mean follow-up duration 7.5 y).
SETTING: The study was conducted at the CF Center of Milan. PATIENTS: The study included 187 patients aged 8-30 years. INTERVENTION: Interventions included 3-hour oral glucose tolerance tests (n = 478) with 30-minute insulin and c-peptide sampling. MAIN OUTCOME MEASURES: Model-derived insulin secretory and sensitivity parameters were measured.
RESULTS: Age was associated with a progressive decrement in insulinemia (at 30 min) and a subsequent increment in glycemia (at 60-90 min), returning at or below baseline (at 180 min). These changes are explained by a progressive reduction in β-cell sensitivity to glucose and a progressive increment in insulin clearance. Fasting and postprandial insulin sensitivity do not seem to be involved. Compared with males, females display higher glucose, insulin, and c-peptide responses with greater insulin secretion, β-cell sensitivity to glucose, insulin clearance, and equal insulin sensitivity.
CONCLUSIONS: A defect in β-cell sensitivity to glucose progressively develops with age, but it is not sex specific and does not explain the worse glucose tolerance reported in females. In contrast, insulin clearance increases with age, especially in females, contributing to the deterioration in glucose tolerance. The effects of age and sex should be considered when evaluating oral glucose tolerance test results in CF patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26057180     DOI: 10.1210/jc.2015-1512

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.

Authors:  Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

2.  Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis.

Authors:  Yaling Yi; Andrew W Norris; Kai Wang; Xingshen Sun; Aliye Uc; Antoinette Moran; John F Engelhardt; Katie Larson Ode
Journal:  Am J Respir Crit Care Med       Date:  2016-10-15       Impact factor: 21.405

3.  Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.

Authors:  Angel Li; Tim Vigers; Laura Pyle; Edith Zemanick; Kristen Nadeau; Scott D Sagel; Christine L Chan
Journal:  J Cyst Fibros       Date:  2018-08-10       Impact factor: 5.482

4.  Characterization of glucose metabolism in youth with vs. without cystic fibrosis liver disease: A pilot study.

Authors:  Maria Socorro Rayas; Kara S Hughan; Rida Javaid; Andrea Kelly; Marzieh Salehi
Journal:  J Clin Transl Endocrinol       Date:  2022-03-21

5.  Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.

Authors:  Insa Korten; Elisabeth Kieninger; Linn Krueger; Marina Bullo; Christa E Flück; Philipp Latzin; Carmen Casaulta; Claudia Boettcher
Journal:  Front Pediatr       Date:  2022-04-21       Impact factor: 3.569

6.  Prepuberal insulin secretory indices are long-term predictors of short adult stature in cystic fibrosis.

Authors:  Alberto Battezzati; Andrea Foppiani; Gianfranco Alicandro; Arianna Bisogno; Arianna Biffi; Giorgio Bedogni; Simona Bertoli; Giulia De Carlo; Erica Nazzari; Carla Colombo
Journal:  Endocr Connect       Date:  2022-05-10       Impact factor: 3.221

7.  Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

Authors:  Katherine Kutney; Shannon B Donnola; Chris A Flask; Rose Gubitosi-Klug; MaryAnn O'Riordan; Kimberly McBennett; Thomas J Sferra; Beth Kaminski
Journal:  World J Hepatol       Date:  2019-12-27

8.  Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.

Authors:  C Colombo; A Foppiani; A Bisogno; S Gambazza; V Daccò; E Nazzari; A Leone; A Giana; A Mari; A Battezzati
Journal:  J Endocrinol Invest       Date:  2021-02-13       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.